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Objective. We prospectively evaluated low-stage breast cancers treated with
neoadjuvant chemotherapy using whole-volume sonography and color Doppler
imaging. Methods. Thirty-four women with breast cancer (mean maximum size,
2.4 cm) received neoadjuvant chemotherapy with doxorubicin and docetaxel.
Targeted whole-volume sonography of tumor sites was performed before and after
chemotherapy to assess mass size, color pixel speed-weighted density, and
American College of Radiology Breast Imaging Reporting and Data System sono-
graphic characteristics. After chemotherapy, tumor sites were excised by lumpec-
tomy or mastectomy. Results. Three (11.3%) of 34 patients had a complete
histologic response. After chemotherapy, correlation was r = 0.716 between final
histologic and sonographic sizes. Compared with histologic residual tumors,
sonography had 4 false-negative results, 3 false-positive results, and 27 true-posi-
tive results (sensitivity, 87%), with no false-negative results among a subgroup of
tumors of 7 mm and larger (sensitivity, 100%). The 3 cases with false-positive
results were histologic fibrosis or biopsy changes. Mean speed-weighted density
was 0.015 before and 0.0082 after chemotherapy (P = .03). After chemotherapy,
vascularity was less common within (P = .06) or adjacent to (P = .009) masses or in
tumor sites (P = .05). Prechemotherapy variables of gray scale characteristics and
vascularity were compared with final histologic size, and all had P > .20.
Conclusions. Postchemotherapy sensitivity of sonography was high for residual
tumors of 7 mm or larger. Correlation was moderate between histologic and sono-
graphic final tumor sizes. False-positive results were caused by fibrosis or biopsy-
related changes. False-negative results occurred with residual tumor size of 6 mm
or smaller. After chemotherapy, vascularity usually decreased, and this was not spe-
cific for complete response. Before chemotherapy, no vascular or gray scale feature
at initial imaging predicted complete responders. Key words: breast cancer; breast
sonography; neoadjuvant chemotherapy.
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ecent clinical trials of women with breast cancer
have shown that treatment with chemotherapy
before definitive surgery (neoadjuvant) results in
equal survival overall when compared with a
surgery-first treatment plan. By reducing tumor bulk
before definitive surgery, neoadjuvant chemotherapy
provides the opportunity for breast conservation and for
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a smaller excision size.1,2 In addition to improving
the rates of breast conservation, a complete
pathologic response to neoadjuvant chemothera-
py has been shown to be a reliable predictor of
overall survival.1,2 Furthermore, access to the pri-
mary tumor during early treatment allows for in
vivo testing and allows for evaluation of chemore-
sponsiveness of the patient’s breast cancer.
However, the selection of candidates for
lumpectomy after completion of chemotherapy
is not straightforward, and the assessment of
tumor response can be difficult. Accurate, readi-
ly available, and cost-effective clinical imaging
techniques to assess tumor extent after neoadju-
vant therapy or to predict response at initial eval-
uation would greatly assist clinical care.1
Physicians use palpation, mammography, mag-
netic resonance imaging (MRI), sonography, and
positron emission tomography (PET)1,3–7 to
assess the clinical response to neoadjuvant
chemotherapy, but results may be conflicting.
For example, the physical examination often sug-
gests a complete therapeutic response, whereas
the mammogram shows extensive residual calci-
fications,7 which may be suggestive of remaining
cancer.
Neoadjuvant chemotherapy is commonly used
to treat locally advanced cancers, but the current
trend is to extend the use of neoadjuvant treat-
ment to T1 tumors.2 Many previous studies
among locally advanced breast cancers have
evaluated the ability of mammography, MRI,
sonography, and PET to distinguish the patho-
logic response to neoadjuvant chemotherapy.3–7
One study also reported that PET could even
predict the response to chemotherapy on the
basis of evidence that tumor blood flow and
metabolism were predictors of response.8
To our knowledge, there are no reports of
imaging studies targeted to low-stage (T1 and
T2) breast cancers that undergo neoadjuvant
chemotherapy. As neoadjuvant chemotherapy
becomes a more widespread treatment, the role
of breast sonography should be elaborated. We
studied lower-stage breast cancers using whole-
volume sonography augmented with color
Doppler imaging. Our purposes were to assess
the accuracy of sonography in detecting residu-
al primary breast malignancy, to evaluate how
gray scale and color Doppler characteristics of
tumors change during chemotherapy, and to
determine whether any of these characteristics
were predictive of response to chemotherapy.
Materials and Methods
Patient Group
Patients were recruited from a multidisciplinary
breast care center at a national comprehensive
cancer center into a trial of neoadjuvant
chemotherapy. This prospective study evaluated
patients who had early-stage operable breast
cancers that were found between January 11,
1999, and August 12, 2002. Institutional Review
Board approval and informed consent were
obtained. Eligibility criteria included women
with core needle biopsy-proved invasive cancers
that were T1, T2, or T3, N0, N1, or N2, and M0.
Women with T4 tumors were excluded. Each
woman was treated with doxorubicin and doc-
etaxel as neoadjuvant chemotherapy, after which
the tumor sites were excised by lumpectomy, or
mastectomy specimens were histologically pro-
cessed and interpreted in the customary way for
breast lesions at our institution. The chemother-
apy consisted of doxorubicin (50 mg/m2) and
docetaxel (75 mg/m2) on day 1, every 3 weeks, for
4 cycles during a 16-week period. Histologic find-
ings were obtained from medical records.
Forty-one women underwent whole-volume
breast sonography including gray scale and color
Doppler imaging of the primary cancer both
before and after chemotherapy. Six patients were
excluded from analysis because their tumors
appeared larger than 4 cm (transducer width),
which made it technically difficult to assess the
vascularity and gray scale features from a single
transducer sweep. One patient was excluded
from analysis because the tumor was incom-
pletely scanned and only partially visible in the
image volume. Thus, the study group consisted
of 34 women (age range, 27–61 years; mean age,
45 years) with invasive cancers of 1 to 4 cm
(mean maximum tumor size, 2.4 cm). 
Sonographic Image Acquisition 
A sonographic examination of each patient was
performed with a GE LOGIQ 700 scanner (GE
Healthcare, Waukesha, WI) using an M12 linear
matrix array scan head (6 MHz Doppler and 9
MHz gray scale). The region that contained the
tumor was scanned, and, on average, this mea-
sured approximately 4 cm in width by 3.5 to 6 cm
in length. Scanning was performed in a manner
previously described by Bhatti et al9 and
LeCarpentier et al.10 The images were acquired at
approximately 0.5-mm intervals in gray scale and
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color Doppler modes. With the use of a compact
hand-driven scanner, the images were acquired at
approximately 0.5-mm intervals in gray scale and
color Doppler modes and interfaced to a personal
computer. To identify the location of the mass for
sonographic imaging before and after chemother-
apy, multiple sources of information were used,
including palpation, clinically obtained mammo-
graphic and sonographic images and their
reports, markers on the skin (tattoo), and biopsy
clips. In addition, the exact location of the mass,
the scan direction, and sonographic settings were
recorded at the initial prechemotherapy research
sonographic scans, and then the scans were per-
formed in the same manner after completion of
chemotherapy. The research sonographic scans
were performed by 1 technologist experienced in
breast sonographic imaging, also trained in mam-
mography. The skin over the breast mass was
coated with gel, and the breast was stabilized by
stretching a 2-mil polyethylene film (also coated
with gel) across the chest to decrease tissue
motion. For color Doppler imaging, the patient’s
electrocardiogram was used to trigger the foot
switch of the GE scanner. Thus, cardiac gating was
used for image capture during systole, which
maximized the Doppler signal. 
Image Post Processing
Sixty to 90 images per scan were stored in the
cine loop and then transferred to a workstation
for post processing. The scan slices were stacked
to render a 3-dimensional (3D) volume. Each 3D
volume was displayed in AVS/Express data visu-
alization software (Advanced Visual Systems,
Waltham, MA) as a series of 3 intersecting planes.
In-house tools designed with AVS/Express
allowed a radiologist to review the image vol-
umes and slices and to determine the margins in
3 dimensions of each mass. The radiologist
(M.A.R.) selected a 3D region of interest (ROI)
that identified the mass in each tissue volume. To
delineate the ROI from the surrounding tissue, a
dynamically positioned and shaped ellipsoidal
3D volume was formed by the AVS/Express soft-
ware, a procedure described previously.9,10 These
ROIs were placed prospectively in the image sets
before the final histologic results at excision were
available. Therefore, the radiologist was blinded
to final histologic outcome at the time of identi-
fication of the masses. The prechemotherapy
sonographic images were used to help assess the
postchemotherapy images in each patient.
Image Analysis
Mass Size and Volumes
These were calculated from the ROIs by in-house
software. 
Mass Characterization
The whole-volume gray scale image sets were ran-
domized, and readers were blinded to patient
information and dates of the scans. Characteristics
of the masses were classified according to the
American College of Radiology Breast Imaging
Reporting and Data System (BIRADS) lexicon
sonographic categories11 and were read by consen-
sus by 2 readers (M.A.R. and S.P.G.). The shapes of
the masses were classified as oval, round, or irreg-
ular. Orientation was classified as either parallel or
not parallel. Margins were classified as either cir-
cumscribed or not circumscribed. The lesion
boundary was classified as either an abrupt inter-
face or echogenic. Echogenicity was classified as
complex, hypoechoic, or isoechoic (no cases were
either anechoic or hyperechoic). Posterior acoustic
features were classified as no posterior acoustic
features, enhancement, shadowing, or a combined
pattern. The ratings for all scans were recorded in a
Microsoft Excel (Microsoft Corporation, Redmond,
WA) spreadsheet and tabulated.
Color Doppler Assessments 
Subjective Measures. By the same readers above,
vascularity was classified from the color Doppler
image volume according to the 4 BIRADS sono-
graphic vascularity categories: “not present”
(defined as in or adjacent to a mass), “present in
the lesion,” “present immediately adjacent to the
lesion,” and “diffusely increased vascularity in
surrounding tissue.”11 If vascularity was present,
1 or more of the other 3 classifications could be
present. Thus, the last 3 categories were not
mutually exclusive. 
Quantitative Measures. The vascularity of each
mass was assessed from the ROI in the color
Doppler image sets by a quantitative computer
method previously described using a formula
designated as speed-weighted pixel density
(SWD).9,10 This formula measures the density of
color pixels in a gray scale volume.
Differences between before and after chemo-
therapy for these vascularity assessments were
analyzed by the t test (for SWD values) and
McNemar test (for subjective ratings).
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Data Analysis 
To determine the accuracy of sonography in
detecting residual tumors after chemotherapy,
sonographic findings after chemotherapy (ie,
presence of a mass and its maximal size) were
compared with histologic reports at final excision
by lumpectomy or mastectomy (ie, presence of
malignant tumor and its maximal size). Each
postchemotherapy sonographic result was then
categorized as true-positive, true-negative, false-
positive, or false-negative. The final histologic
size was compared with the postchemotherapy
sonographic size with the use of a correlation
coefficient. Final histologic size was compared
with the prechemotherapy subjective classifica-
tions (BIRADS sonographic categories) of the
gray scale and color Doppler characteristics and
with the color Doppler SWD values to determine
whether any feature predicted response to
chemotherapy. Categorical variables were ana-
lyzed with 1-way analysis of variance, and con-
tinuous variables were analyzed with linear
regression. 
Results 
Histologic Results at Final Excision Compared
With Postchemotherapy Sonographic Results
After completion of chemotherapy, 3 of the 34
patients had no residual invasive or intraductal
cancer at histologic examination (ie, complete
response), and 31 patients had residual cancer
(maximal size range, 0.2 cm of ductal carcinoma
in situ to 3.5 cm of invasive cancer; mean, 1.2
cm). Therefore, compared with mean maxi-
mum size by sonography before chemotherapy
(2.4 cm), there was, on average, a 50% decrease
in maximum tumor size. The postchemothera-
py mean maximum size by sonography in the
entire group (34 cases) was 1.2 cm, which was
the same as the final mean maximum histolog-
ic size of 1.2 cm. The maximum sonographic
size of the masses was compared with the max-
imum histologic size, and these values are sum-
marized in Figure 1. There was moderate
correlation between the sonographic values
and the histologic values (r = 0.716; P ≤ .002).
This graph also depicts the cases that had sono-
graphic false-negative (4), false-positive (3), and
true-positive (27) results. Three cases had sono-
graphic masses at the end of chemotherapy,
without residual histologic tumors (the com-
plete responders); therefore, these were the 3
cases with false-positive sonographic results.
The histologic reports for these cases indicated
the presence of fibrosis (2 cases) and biopsy-
related change (1 case) (Figure 2, A and B).
Because no sonographic mass was identifiable
after chemotherapy despite histopathologic
evidence of tumor cells, 4 cases had false-nega-
tive results; all were 6 mm or smaller in maxi-
mum histologic size.
A subgroup of cases with a maximum histolog-
ic size of residual cancer of 0.7 cm or larger (23
cases) all had a sonographic mass. Therefore,
there were no false-negative sonographic results
in this subgroup. The sonographic size was with-
in 1 cm of the final histologic size in 28 (82%) of
34 patients. Sonography underestimated the
extent of residual cancer by greater than 1 cm in
2 (6%) patients and overestimated it by greater
than 1 cm in 4 (12%) patients, 2 of whom had the
false-positive results (complete responders). In 1
of these cases, the pathology report indicated
that the exact size was very difficult to deter-
mine. In the cases with true-positive results, the
initial mean volume was 6475 mm3 and the final
mean volume was 1342 mm3 (79% decrease). 
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Figure 1. Postchemotherapy mass size by sonography compared
with histologic size. Diamonds indicate true-positive; squares,
false-positive; and triangles, false-negative (r = 0.716; P ≤ .002). 
Changes in Mass Characteristics and Color
Doppler Signal During Chemotherapy
Mass Characteristics 
The BIRADS gray scale characteristics are summa-
rized in Table 1, grouped by before and after
chemotherapy and according to true-positive,
false-positive, and true-negative results. Among
the 27 cases with true-positive results (those hav-
ing a residual tumor at final excision and a sono-
graphic mass after chemotherapy), 26 were
evaluated (1 case was excluded from this analysis
because 1 computer file was lost at the time of
analysis). Overall, 20 (77%) of 26 masses changed
in 1 gray scale characteristic or more, whereas 6
(24%) did not change in any gray scale feature. The
most common change was in posterior acoustic
features (12 cases), and change in shape was occa-
sionally dramatic (Figures 3, A and B, and 4, A and
B). There was no consistent pattern of change
among the BIRADS sonographic features. There
were no gray scale features that were useful to dis-
tinguish false-positive from true-positive results.
In statistical analysis, no gray scale characteris-
tic at initial imaging (eg, orientation, margin,
lesion boundary, echo pattern, and posterior
acoustic features) was significant for predicting
final histologic size, with P values for these anal-
yses ranging from .21 to .91. 
Color Doppler Changes
The objective values (measured as SWD)
before and after chemotherapy are summa-
rized in Table 2. Among the cases with true-
positive results, mean SWD was lower after
chemotherapy, suggesting that, overall, vascu-
larity decreases with chemotherapy (Figure 5,
A–C). However, in a few cases, SWD was greater
after chemotherapy, and in some cases it did
not significantly change. Before chemotherapy,
6 masses had no measurable color Doppler sig-
nal, and after chemotherapy, 12 masses had no
measurable color Doppler signal. Two of the 3
cases of complete responders had a low but
measurable color Doppler signal at the end of
chemotherapy.
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Figure 2. Histologic complete response. A, Before chemotherapy, the breast cancer is a taller-than-wide hypoechoic mass with
indistinct margins and slight shadowing. B, After, chemotherapy, there is a smaller hypoechoic oval mass with indistinct margins,
which simulated residual malignancy and was fibrosis at final histologic examination. 
A B
It should be observed that changes in these
SWD values do not reflect volume or size changes
because the SWD measure is the rate of color
pixels to gray scale pixels in a given volume.
Therefore, a change in the vascularity of a mass
as measured by SWD is independent of a change
in the size of a mass.
The subjective ratings before and after chemo-
therapy are summarized in Table 3. This shows
that the color Doppler signal (ie, vascularity) sig-
nificantly decreased after chemotherapy in 3 of
the 4 categories, and after chemotherapy, half of
the cases had absent vascularity.
Before chemotherapy, neither subjective vascu-
larity ratings nor the SWD values appeared to
correlate to the final histologic size or to a com-
plete histologic response. For example, among
the 6 cases that initially had absent vascularity,
the final histologic mean size was 1.4 cm (range,
0.7–3.2 cm), and among the 6 cases with the
highest vascularity, the final histologic mean size
was 1.5 cm (range, 0–3.5 cm). Thus, initial vascu-
larity did not predict the tumor response to
chemotherapy. It may be noted that the 3 cases
that had a complete histologic tumor response
(no residual cancer) had at initial imaging com-
paratively low SWD values and no vascularity in
the lesion. However, because of small numbers of
cases that were complete responders, this was
not statistically significant. When the quantita-
tive and subjective vascularity characteristics
were compared with final histologic size, P values
were not significant and ranged from .27 to .70.
At the end of chemotherapy, among the 12
masses with absent vascularity subjectively and
objectively, 2 had no residual cancer, 1 had 0.2
mm of ductal carcinoma in situ, and 9 had resid-
ual invasive cancer (mean maximum size, 1.1
cm; range 0.1–2.8 cm). Therefore, the absence of
vascularity at the end of chemotherapy was com-
mon and was not specific for a complete
response.
Discussion 
Neoadjuvant chemotherapy increases the
chance of breast conservation, decreases the
amount of excised breast tissue necessary for
treatment, and allows the observation of the
chemoresponsiveness of breast cancers.1,2,12 The
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Table 1. Sonographic BIRADS Categories of the Sonographic Masses
True-Positive False-Positive* False-Negative
(n = 26) (n = 3) (n = 4)
Characteristic Before After Before After Before After
Margins
Circumscribed 11 9 2 0 0 NA
Not circumscribed 15 17 1 3 4 NA
Shape
Round 3 1 2 0 0 NA
Oval 13 16 1 2 3 NA
Irregular 10 9 0 1 1 NA
Orientation
Parallel 12 15 1 2 1 NA
Not parallel 14 11 2 1 3 NA
Echo pattern
Complex 3 2 0 0 0 NA
Hypoechoic 19 18 2 2 4 NA
Isoechoic 4 6 1 1 0 NA
Posterior acoustic features
None 4 14 0 2 2 NA
Enhancement 9 4 1 0 1 NA
Shadowing 9 8 2 1 1 NA
Combined 4 0 0 0 0 NA
Lesion boundary
Abrupt 16 18 2 3 2 NA
Echogenic 10 8 1 0 2 NA
After indicates after completion of the course of chemotherapy; Before, before administration of chemotherapy; and
NA, not applicable.
*At final histologic examination, there was no residual tumor, although a mass was visible on sonography.
development of sensitive and specific imaging
methods to evaluate residual disease could be
helpful for oncologists to spare patients with a
complete histologic response from surgery, to
plan surgical excision, or to determine whether
more or alternative chemotherapy is needed.1
Physical examination and mammography have
reproducibility and sensitivity limitations in
assessing tumor response.1,7 There are several
research studies that have evaluated whether
various imaging studies can show tumor
responsiveness of locally advanced breast can-
cers to neoadjuvant chemotherapy. We studied
patients with early-stage cancers because a
neoadjuvant research protocol at our institution
made this treatment available to patients with
tumors as small as stage T1. Such a group facili-
tates detailed sonographic analyses compared
with patients with large locally advanced tumors.
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Figure 3. Histologic complete response: change in gray scale appearance after chemotherapy. A, Before chemotherapy, the breast
cancer is an irregular hypoechoic mass with increased through-transmission. B, After chemotherapy, there is a smaller hypoechoic
mass of a similar shape, now with shadowing.
A B
Figure 4. Change in gray scale appearance after chemothera-
py. A, Before chemotherapy, the breast cancer is a circumscribed
hypoechoic round mass. B, After chemotherapy, there is a tubu-
lar flat hypoechoic mass, which was residual cancer. 
A
B
At completion of chemotherapy, the correlation
between final histologic maximum size and
sonography was moderate (0.716), which is inter-
mediate compared with the correlation coeffi-
cients of 0.48 to 0.92 in prior studies of untreated
breast cancers and coefficients of 0.57 to 0.89 in
locally advanced tumors treated with neoadju-
vant chemotherapy.6,13–18 There are many differ-
ences between the latter studies and our study.
For example, some were performed with more
than 1 sonography machine and more than 1
sonographer or radiologist. In addition, unlike
our study using whole-volume images, 2-
dimensional static images were obtained. Color
Doppler sonography was performed in only 1
study, and some radiologists were not blinded
to other clinical or imaging results. Our correla-
tion coefficient and estimations of residual
tumor are comparable with those reported for
MRI.17,19 The correlation between imaging
results and histologic results after neoadjuvant
chemotherapy is probably affected by the type
of chemotherapy. Tumor shrinkage in a doc-
etaxel treatment group is reported to result in
multiple microscopic nests of tumors rather
than a single nodular lesion.20 This effect of doc-
etaxel may also explain the false-negative results
in our study. Comparison of tumor size between
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Table 2. Mean Vascularity of Masses as Measured by SWD 
Before After
Result Chemotherapy Chemotherapy P*
True-positive (n = 27) 0.0150 0.0082 .03
False-positive (n = 3) 0.0042 0.0014 .22
False-negative (n = 4) 0.0006 NA NA
NA indicates not applicable.
*Student t test. 
Figure 5. Decrease in color flow Doppler signal and change in
gray scale features after chemotherapy. A and B, Before
chemotherapy, the breast cancer appears as a hypoechoic cir-
cumscribed lobulated mass with some posterior acoustic
enhancement and a profuse color Doppler signal within it and
adjacent to it. C, After chemotherapy, there is an indistinctly
margined hypoechoic mass with some shadowing. The color
Doppler signal was absent in the mass and was decreased in the




sonography and histologic examination may be
more difficult after chemotherapy because
tumors may become smaller and multifocal,
making them less discrete on sonography and
harder to measure at both sonography and his-
tologic examination. Forouhi et al3 reported that
sonography was superior to clinical examination
in measuring breast tumor size after chemother-
apy and reported a higher correlation coefficient,
0.89. This higher correlation coefficient is likely
due to the systematic processing of histologic
specimens in their study, wherein size was mea-
sured from serial thin sections of fresh resected
specimens. In our study group, sonography was
sensitive in detecting residual tumors of 7 mm
or larger. However, sonography was not able to
distinguish between fibrosis, biopsy-related
changes, and residual cancer. Furthermore,
chemotherapy-induced histologic changes may
contribute to the less than perfect correlation
between the sonographic measurement of final
maximum tumor size and the histologic mea-
surement.21 For example, fibrous tissue is a com-
mon histologic finding in tumor sites after
neoadjuvant chemotherapy,22,23 which can cause
a visible mass on sonography and may cause the
sonographic volume to be larger than the histo-
logic volume of residual cancer.23
Color Doppler sonography has been shown to
show neovascular characteristics in breast can-
cers, and some authors suggested that it may
have the potential to measure tumor response.18
Huber et al18 studied color Doppler sonography
in locally advanced breast cancers and found
high correlation between histologic results and
semiquantitative color Doppler results, with 1
patient who had a complete response having
absent vascularity in a mass (fibrosis). A limita-
tion in these previous studies as well as our own
study was the small proportion of patients
(10%–15%) who completely responded to the
neoadjuvant chemotherapy. In our study, there
were 9 residual cancers up to 2.5 cm in size that
had a sonographic mass without any vascularity.
Therefore, the finding of a mass without vascu-
larity was not specific for a complete tumor
response in our study group. The vascularity
measures decreased in most of our cases after
chemotherapy but were not useful to indicate
whether a complete response had occurred. The
pathophysiologic explanation for the decrease in
vascularity in these cases was not studied and
remains unknown. It could possibly be related to
the decrease in tumor size during chemotherapy,
chemotherapy’s effect on angiogenesis, or both.
Differences between our study and the report by
Huber et al18 about the usefulness of color
Doppler sonography in assessment of residual
cancer may be due to chemotherapy regimens,
with taxanes not previously studied with color
Doppler sonography. Docetaxel may have
antiangiogenic activity, which may be a reason
for the decrease in the vascular measures that
occurred in most of our cases, an effect that was
too common to indicate a complete histologic
response.24 It has been suggested that hypervas-
cularity and hypermetabolic activity might be
indicators of the likelihood of tumor response.
This is based on the hypothesis that tumors with
poor perfusion may not receive adequate deliv-
ery of systemic therapy or that underperfused
tumors might be hypoxic.8,25 Hypoxia has been
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Table 3. Vascularity of Masses Determined by BIRADS Vascularity Classifications 
BIRADS Vascularity Before After
Classification Chemotherapy Chemotherapy P*
Entire group (n = 34)
Not present, n (%) 7/34 (21) 17/34 (50) .05
Increased in surrounding tissue, n (%) 7/34 (21) 7/34 (21) NS
Present adjacent to lesion, n (%) 23/34 (68) 10/30 (33)† .009
Present in lesion, n (%) 11/34 (32) 3/30 (10)† .06
Subgroup of complete responders (n = 3)
Not present, n (%) 1 (33) 2 (67) NS
Increased in surrounding tissue, n 0 0 NS
Present adjacent to lesion, n (%) 2 (67) 1 (33) NS
Present in lesion, n 0 0 NS
NS indicates not significant.
*McNemar test. 
†Four cases did not have a mass after chemotherapy.
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associated with aggressive tumor behavior and
poor tumor responsiveness to chemotherapy.8,25
Contrary to this hypothesis, in our study group,
high vascularity at initial imaging did not predict
tumor response, and the complete responders
had comparatively low vascularity.
To our knowledge, there are no previous stud-
ies that have evaluated whether any imaging
characteristics at initial imaging can predict the
response to chemotherapy. We did not find that
any gray scale or vascular characteristic predict-
ed tumor response, although the statistical eval-
uation was limited by the small numbers of
complete responders. We also found that gray
scale characteristics commonly change after
chemotherapy but not in a predictable way.
Some changes may be due to shrinking tumor
size, development of fibrosis or cellular necrosis,
and the tumor’s becoming multifocal. Therefore,
the appearance of the tumor after chemotherapy
may be rather different, and identifying the
location with tissue markers is important for
postchemotherapy localization. Gray scale char-
acteristics also do not distinguish the false-posi-
tive results from the true-positive residual
tumors. A limitation of our study was that tumors
were histologically fixed in the usual way, and
paraffin fixation might alter tumor size. Because
pathologic evaluation of tumor size remains the
standard for evaluation of a residual tumor after
chemotherapy, there may be a role for develop-
ment of new histologic mapping of the tumor bed
to more precisely compare imaging studies in
these patients.21 Another limitation of our study is
that tumors were not analyzed for microvessel
density; hence, we cannot compare the color
Doppler results with histologic vascularity.
In summary, we found that, after chemothera-
py, the maximum tumor size at final histologic
examination correlated quite well with the final
sonographic size among cancers that were 7 mm
or larger in maximal size. However, sonographic
imaging yielded false-negative results in detect-
ing residual tumors that were smaller than this
threshold size. On the basis of our findings and
those of other studies, we hypothesize that the
histologic effects of docetaxel may contribute to
false-negative gray scale sonographic results, and
that antiangiogenic effects make a decrease in
vascularity a nonspecific common finding. The
presence of a mass after treatment may or may
not signify a viable tumor because fibrosis can
falsely mimic a tumor, and no gray scale or vas-
cular characteristic was useful to distinguish
these fibroses from residual tumors. This means
that postchemotherapy biopsy would be neces-
sary to determine with confidence whether a
residual tumor was present. Gray scale features
often change, and the appearance of the mass
after chemotherapy may be quite different com-
pared with initial imaging.
Sonography has advantages for assessment of
breast cancers that are treated with neoadjuvant
chemotherapy. Compared with mammography,
evaluation of the breast by sonography is not lim-
ited by mammogram density, and nearly all can-
cers are evident at initial imaging. Compared
with MRI, all patients are able to undergo sono-
graphic evaluation; sonographically guided
biopsies are simpler for assessing chemotherapy
response; and it is a relatively low-cost modality.
Radiologists and sonographers who perform
breast sonography should be aware of the chang-
ing appearance of breast cancers during
chemotherapy and of the advantages and limita-
tions of sonography in assessing tumor response. 
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